| Item Type | Name |
|
Concept
|
Drug Administration Schedule
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
|
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
|
Academic Article
|
Mineralocorticoid insufficiency due to suramin therapy.
|
|
Academic Article
|
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
|
|
Academic Article
|
New phase I trial methodology.
|
|
Academic Article
|
Suramin: is adaptive control necessary?
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
|
|
Academic Article
|
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
|
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
|
|
Academic Article
|
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
|
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
|
Academic Article
|
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
|
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
The value meal: how to save $1,700 per month or more on lapatinib.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
|
|
Academic Article
|
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
|
Academic Article
|
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
|
Academic Article
|
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
|
|
Academic Article
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
|
Academic Article
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
|
Academic Article
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
|
|
Academic Article
|
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
|
|
Academic Article
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
|
|
Academic Article
|
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
|
|
Academic Article
|
Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations.
|
|
Academic Article
|
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
|
|
Academic Article
|
Alternative dosing regimens for atezolizumab: right dose, wrong frequency.
|
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
|
Academic Article
|
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
|
|
Academic Article
|
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions.
|